

SCIENTIFIC ARTICLES / CLINICAL STUDIES

Sodium Phenylbutyrate **(4-Phenylbutyric Acid, Sodium Salt)**

ADRENOLEUKODYSTROPHY (ALD)

Baarine M, Ragot K, Genin EC, Hajj HE, Trompier D, Andreoletti P, Ghandour MS, Menetrier F, Cherkaoui-Malki M, Savary S, Lizard. Peroxisomal and mitochondrial status of two murine oligodendrocytic cell lines (158N,158JP): potential models or the study of peroxisomal disorders associated with dysmyelination processes. *J Neurochem* Oct 2009;111(1):119-31

Brose RD, Shin G, McGuinness MC, Schneidereith T, Purvis S, Dong GX, Keefer J, Spencer F, Smith KD. Activation of the stress proteome as a mechanism for small molecule therapeutics. *Hum Mol Genet* Oct 2012 1;21(19):4237-52.

Girard S, Bruckert E, Turpin G. Endocrine disease in adrenoleukodystrophy. *Ann Med Intern (Paris)* Feb 2001;152(1):15-26.

Gondcaille C., Depreter M. Fourcade S., Lecca M.R., Leclercq S., Martin P.G.P., Pineau T., Cadepond F., EIEtr M., Bertrand N., Beley A., Duclos S., De Craemer D., Roels F., Savary S., Bugaut M., Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator. *The Journal of Cell Biology*, Vol. 169, No. 1, 93-104, April 2005.

McGuinness MC, Zhang HP, Smith KD Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy. *Mol Genet Metab* Sept-Oct 2001;74(1-2):256-63

Wei H., Kemp S, McGuinness MC, Moser AB, Smith KD. Pharmacological induction of Peroxisomes in Peroxisome Biogenesis Disorders. *Ann Neurol*, 47:286-296. 2000.

AGING

Burzynski, S.R. Aging: gene silencing or gene activation? *Med Hypotheses* 2005; 64 (1): 201-208

Kang H-L., Benzer S., Min K-T. Life extension in Drosophila by feeding a drug. *PNAS* Jan 22, 2002, Vol. 99 No. 2, (838-843).

Wagner, G. Towards a life prolonging pill? Small molecules with anti-ageing properties. *Current Drug Targets* 2006; 7 (11): 1531-1537

ALZHEIMER'S DISEASE

Barbero-Camps E, Fernandez A, Baulies A, Martinez L, Fernandez-Checa J, Colell A. Endoplasmic reticulum stress mediates amyloid β neurotoxicity via mitochondrial cholesterol trafficking. *Am J Pathol* July 2014;184(7):2066-81

Corbet, G., Roy A., Pahan K. Sodium Phenylbutyrate Enhances Astrocytic Neurotrophin Synthesis via Protein Kinase C (PKC)-mediated Activation of cAMP-response Element-binding Protein (CREB) Implications for Alzheimer Disease Therapy. The American Society for Biochemistry and Molecular Biology 2013

Cuadrado-Tejedor M, Garcia-Osta A, Ricobaraza A, Oyarzabal J, Franco R. Defining the mechanism of action of 4-phenylbutyrate to develop a small-molecule-based therapy for Alzheimer's disease. *Curr Med Chem* 2011;18(36):5545-53.

Cuadrado-Tejedor, M., Ricobaraza A., Torrijó R., Franco R., Garcia-Osta, A., Phenylbutyrate is a dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease.

Hippocampus. 2012 May; 22(5):1040-50. doi: 10.1002/hipo.20883. Epub 2010 Nov 10.

Liu N, Qiang W, Kuang X, Thuillier P, Lynn WS, Wong Paul KY. The peroxisome proliferator phenylbutyric acid (PBA) protects astrocytes from ts1 MoMuLV-induced oxidation cell death. *J Neurovirol* Aug 2002;8(4):318-25

Multifaceted Drug that Exerts Neuroprotective Effects and Reverses the Alzheimer's Disease-like Phenotype of a Commonly Used Mouse Model. *Current Pharmaceutical Design*, Vol.19, No. 28, pp. 5076-5084(9). November 28, 2013

Osta, A. Phenylbutyrate Ameliorates Cognitive Deficit and Reduces Tau Pathology in an Alzheimer's disease Mouse Model. *Neuropsychopharmacology* January 14, 2009;doi:10.1038/npp.2008.229

Ricobaraza A., Cuadrado-Tejedor M., Marco S., Perez-Otano I., Garcia-Osta A. Phenylbutyrate rescues

Ricobaraza, A., Cuadrado-Tejedor, M., Pérez-Mediavilla, A., Frechilla, D., Del Río, J., García-

MUSCLE

Begam M, Abro VM, Mueller AL, Roche JA. Sodium 4-phenylbutyrate reduces myofiber damage in a mouse model of Duchenne muscular dystrophy. *Appl Physiol Nutr Metab* Oct 2016;41(10):1108-1111

Hayashi G, Labelle-Dumais C, Gould DB. Use of sodium 4-phenylbutyrate to define therapeutic parameters for reducing intracerebral hemorrhage and myopathy in Col4a1 mutant mice. *Dis Model Mech* Jul 2018;11(7):dmm034157

Nogalska, A., D'Agostine, C., Engel, W.K., Askanas, V. Sodium Phenylbutyrate reverses lysosomal dysfunction and decreases amyloid- β 42 in an in vitro-model of inclusion-body myositis. *Neurobiology of Disease*, Volume 65, Pages 93-101, May 2014.

AMYOTROPHIC LATERAL SCLEROSIS (ALS)

Brujin LI, Cudkowicz, M. Therapeutic targets for amyotrophic lateral sclerosis: Current treatments and prospects for more effective therapies. *Expert Rev Neurother* 2006; 6 (3): 417-428.

Carri, MT, Grignaschi, G, Bendotti, C. Targets in ALS: designing multidrug therapies. *Trends Pharmacol Sci* 2006; 27 (5): 267-273.

Corman A, Jung B, Häggblad, Bräutigam, Lafarga V, Lindemalm L, Hühn, Carreras-Puigvert J, Fernandez-Capetillo O. A Chemical Screen Identifies Compounds Limiting the Toxicity of C9ORF72 Dipeptide Repeats. *Cell Chem Biol.* Feb 2019;26(2):235-243.e5.

Cudkowicz, M.E., Aneres, P.L., et al. Macdonald, S.A., et al. Phase 2 study of sodium Phenylbutyrate in ALS. *Amyotroph Lateral Scler.* 2009; 10(2):99-106

Cudkowicz, ME, Andres, PL, Choudry, R, MacDonald, SA, Zhang, H, Schoenfeld, D, Ferrante, RJ. Safety and dose escalating study of oral sodium phenylbutyrate in subjects with ALS *Neurology* 2007; 68 (12, Suppl. 1): A90.

Del Signore, S.J., Amante, D.J., Kim, J., Stack, E.C., Goodrich, S., Cormier, K., Smith, K., Cudkowicz, M.E., Ferrante, R.J. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. *Amyotrophic Lateral Sclerosis*, Volume 10,, Issue 2, April 2009.

DiBernardo, A.B., Cudkowicz, M.E. Translating preclinical insights into effective human trials in ALS. *Biochimica et Biophysica Acta* 1762 (2006) 1139-1149.

Petri S., Kiaei M., Kipiani K., Chen J., Calingasan N.Y., Crow J.P., Beal M.F., Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. *Neurobiology of Disease* 22, 40-49 (2006).

Ryu H, Smith K, Camelo S.I., Carreras I., Lee J., Iglesias A.H., Dangond F., Cormier K.A., Cudkowicz M.E., Brown Jr. R.H., Ferrante R.J. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. *Journal of Neurochemistry*, 2005, 93, 1087-1098.

Scott, S, Kranz, JE, Cole, J, Lincecum, JM, Thompson, K, Kelly, N, Bostrom, A, Theodoss, J, Al-Nakhala, BM, Vieira FG, Ramasubbu, J, Heywood, JA. Design, power and interpretation of studies in the standard murine model of ALS. *Amyotroph Lateral Scler* 2008; 9 (1): 4-15.

Traynor BJ, Bruijn L, O'Neill F, Fagan G, Cudkowicz ME. Neuroprotective agents for clinical trials in ALS: a systematic assessment. *Neurology* 2006; 67(1):20-27

Traynor, BJ, Bruijn, L, Conwit, R, Beal, F, O'Neill, G, Fagan, SC, Cudkowicz, ME. *Neurology* 2006; 67 (1): 20-27.

BLOOD

Almeida, A., Murakami, Y., Baker, A., Maeda, Y., Roberts, I., Kinoshita, T., Layton, DM, Karadimitria, A. Targeted Therapy for Inherited GPI Deficiency. *The New England Journal of Medicine* 2007; 356:1641-7

Tveten K, Holla OL, Ranheim T, Berge KE, Leren TP, Kulseth MA. 4-Phenylbutyrate restores the functionality of a misfolded mutant low-density lipoprotein receptor. *FEBS J* 2007;274(8):1881-1893.

TvetenK, Holla OL, Renheim T, Berge KE, Leren TP, Kulseth MA. Rescue of the low density lipoprotein receptor 2A mutant G544V by 4-Phenylbutyrate. *Molecular chaperones and the heat shock response* 2006;187.

CANCER

Al-Keilani MS, Alzoubi KH, Jaradat SA. The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib or gefitinib on resistant NSCLC cells. *Clin Pharmacol* Oct 2018;10:135-140

Ammerpohl, O; Trauzold, A; Schniewind, B; Griep, U; Pilarsky, C; Grutzmann, R; Saeger, H-D; Janssen, O; sipos, B; Kloppel, G; Kalthoff, H. Complementary effects of HDAC inhibitor 4-PB on gap junction

communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. *Br J Cancer* 2007; 96(1):73-81.

Appelskog I.B., Ammerpohl O., Svechnikova I.G., Lui W-O., Almqvist P.M., Ekström T.J. Histone deacetylase inhibitor 4-phenylbutyrate suppresses GAPDH mRNA expression in glioma cells. *International Journal of Oncology* 24:1419-1425, 2004.

Asklune, T., Appelskog I.B., Ammerpohl O., Ekstron T.J., Almqvist, P.M. Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication in human glioblastoma cells. *European Journal of Cancer*, 2004 Vol 40, No. 7.

Baker M J, Brem S, Daniels S, Sherman B, Phuphanich S. Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate. *J Neuro-Oncology*; 59:239-242, 2002.

Belinsky S.A., Klinge D.M., Stidley C.A., Issa J-P., Herman J.G., March T.H., Baylin S.B., Inhibition of DNA Methylation and Histone Deacetylation Prevents Murine Lung Cancer. *Cancer Research* (63) 7089-7093, November 1, 2003.

Belinsky S.A., Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. *Carcinogenesis* Vol. 26, No. 9 (1481-1487) 2005.

Berg S., Serabe B., Aleksic A., Bomgaars L., McGuffey L., Dauser R., Durfee J., Nuchtern J., Blaney S. Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate. *Cancer Chemother Pharmacol.* 47: 385-390. February 2001.

Beyer, SJ; Kulp, SK; Baird, M; Auer, H; Kornacker, K; Chen, C-S; Beer, DG; Kresty, LA. The effects of a phenylbutyrate-derived histone deacetylase inhibitor (HDAC-42) on acid-induced gene expression patterns of SEG-1 human esophageal adenocarcinoma cells. *Proceedings of the American Association for Cancer Research Annual Meeting 2006*; 47:1128-1129.

Boivin A-J., Momparler L.F., Hurtubise A., Momparler R.L.. Antineoplastic action of 5-aza-2'-deoxycytidine and phenylbutyrate on human lung carcinoma cells. *Anti-Cancer Drugs.* Vol 13 (869-874) 2002.

Brock, MV. Clinical aspects of molecular biology for the diagnosis and treatment of esophageal cancer. *Esophagus* 2006; 3(3):91-94.

Burkitt, Kyunghee and Ljungman, Mats. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin. *Molecular Cancer* 7:24, March 2008.

Burzynski, SR, Lewy, RI, Weaver, R, Janicki, T, Jurida, G, Khan, M, Larisma, CB, Paszkowiak, J, , Szymkowski, B. Long-Term Survival and Complete Response of a Patient With Recurrent Diffuse Intrinsic Brain Ctem Glioblastoma Multiforme. *Integrative Cancer Therapies*, 3(3); 2004 pp. 257-261.

Calvaruso G, Carabillo M, Guiliano M, Lauricella M, D'Anneo A, Vento R, Tesoriere G. Sodium phenylbutyrate induces apoptosis in human retinoblastoma Y79 cells: The effect of combined treatment with the topoisomerase I-inhibitor topotecan. *Int. Journal of Oncology* 18: 1233-1237, 2001.

Caraway, HE; Gore, SD. Addition of histone deacetylase inhibitors in combination therapy. *J. Clin Oncol* 2007; 25(15):1955-1956.

Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen TL, Grochow LB, Donehower RC. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. *Clin Cancer Res.* 7(10):3047-55, Oct 2001

Chang T-H, Szabo E., Enhanced Growth Inhibition by Combination Differentiation Therapy with Ligands of Peroxisome Proliferator-activated Receptor- γ and Inhibitors of Histone Deacetylase in Adenocarcinoma of the Lung. *Clinical Cancer Research* Vol. 8, 1206-1212, April 2002.

Chen WQ, Feng FL, Gu HB, et al. Effect of sodium phenylbutyrate on the apoptosis of human tongue squamous cancer cell line and expression of p21 and surviving genes. *Zhonghua Kou Qiang Yi Xue Za Zhi*, July 2010; 45(7):416-20

Christov, K; Grubbs, C; Juliana, M; Lubet, R. Correlation of the preventive/therapeutic efficacy of agents in the methylnitrosourea (MNU) mammary cancer model with changes in cell proliferation and apoptosis following short-term treatment. *Proceedings of the American Association for Cancer Research Annual Meeting 2007*; 48:997.

Christov, K; Grubbs, C; Lubet, R; Altered cell proliferation and apoptosis as biomarkers for identifying preventive/therapeutic agents against chemically induced mammary cancers. *Breast Cancer Research and Treatment 2006*; 100(Suppl. 1):S58.

Christov, Konstantin, Grubbs, Clinton J; Shilkaitis, Anne, Juliana, M Margaret; Lubet, Ronald A. Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model. *Clin Cancer Res 2007*; 13(18 Part. 1):5488-5496.

Chung, Yih-Lin, Wang, Ae-June, Yao, Lin-Fen, Antitumor Histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy. *Molecular Cancer Therapeutics 2004*; 3(3):317-325

Clarke K.O., Ludeman S.M., Springer J.B., Colvin O.M., Lea M.A., Harrison L.E. Exposure to a deuterated analogue of Phenylbutyrate retards S-phase progression in HT-29 colon cancer cells. *Journal of Pharmaceutical Sciences*, Vol. 91, No. 4, April 2002.

Claus, R; Router, B, Loubbert, M. Targets of epigenetics therapy-Gene reactivation as a novel approach in MDS treatment. *Cancer Treat Rec 2007*; 33(Suppl. 1):S47-S52.

Cortez, CC; Jones, PA. Chromatin,cancer and drug therapies. *Mutat Res-Fundam Mol Mech Mutagen 2008*;647(1-2):44-51.

Cosentini E, Haberl I, Pertschy P, Teleky B, Mallinger R, Baumgartner G, Wenzl E and Hamilton G. The differentiation inducers phenylacetate and phenylbutyrate modulate camptothecin sensitivity in colon carcinoma cells in vitro by intracellular acidification. *International Journal of Oncology 19*: 1069-1074, 2001

Cunha De Santis , G; de Barros Tamarozzi, M; Sousa, RB; Moreno, Se; Secco, D; Garcia, AB; Lima, ASG; Faccioli, LH; Falcao, RP; Cunha, FQ; Rego, EM. Adhesion molecules and Differentiation Syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. *Haematologica 2007*; 92(12):1615-1622.

D-C Zhou, Kim SH, Ding W, Schultz C, Warrell R P, Jr, and Gallagher R E. Frequent mutations in the ligand-binding domain of PML-RAR after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. *Blood*, Feb 2002; 99: 1356 - 1363.

De-shum, Pan, Wei-qiang, Chen. The effects of sodium phenylbutyrate (SPB) on the expression of p21 and survivin genes on human tongue squamous cancer cell line Tca8113. *Chinese Pharmacological Bulletin*, February 2010

Du H-L., Qi Y., Shi Y-J., Bu D-F., Wu S-L. Apoptosis and Re-expression of p16 Gene in the Myeloma Cell Line U266 Induced by Synergy of Histone Deacetylase Inhibitor and Demethylating Agent. *Chinese Journal of Cancer*, 2002, 21(10):1057-1061.

Dyer E.S., Paulsen M.T., Markwart S.M., Goh M., Livant D.L. and Ljungman M. Phenylbutyrate inhibits the invasive properties of prostate and breast cancer cell lines in the sea urchin embryo basement membrane invasion assay. *Int. J. Cancer*: 101, 496-499 (2002).

Emionite L., Galmozzi F., Grattarola M., Boccardo F., Vergani L, Toma S., Histone Deacetylase Inhibitors Enhance Retinoid Response in Human Breast Cancer Cell Lines. *Anticancer Research 24*: 4019-4024 (2004).

Entin-Meer, M; Rephaeli, A; Yang, X; Nudelman, A; Haas-Kogan, DA. AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. *Cancer Lett* 2007; 253(2):205-214.

Estey, E. New drugs in acute myeloid leukemia. *Seminars in Oncology* 2008;35(4):439-448.

Fadeev NP, Kharisov RI, Kovan'ko EG, Pustovalov YI. Study o Antitumor Activity of Sodium Phenylbutyrate, Histon Deacetylase Inhibitor on Ehrlich Carcinoma Model. *Bull Exp Biol Med Sep* 2015;159(5):652-4

Feinman R., Clarke, K.O., Harrison LE. Phenylbutyrate-Induced Apoptosis is Associated with Inactivation of Nf- κ B in HT-29 colon cancer cells. *Cancer Chemother Pharmacol* (2002) 49:27-34.

Finzer P., Stöhr M., Seibert N., Rösl F., Phenylbutyrate inhibits growth of cervical carcinoma cells independent of HPV type and copy number *J. Cancer Res. Clin. Oncol.* (2003) 129:107-113.

Fouladi, M. Histone deacetylase inhibitors in cancer therapy. *Cancer Investigation* 2006;24(5):521-527.

Galm, O; Herman, JG; Bbaylin, SB. The fundamental role of epigenetics in hematopoietic malignancies. *Blood Rev* 2006;20(1):1-13.

Gao, J; Ruan, X; Pan, X; Xu, F; Lei, D; Liu, D. The effect of sodium phenylbutyrate to agents used in induction chemotherapy on laryngeal carcinoma cells Hep-2 in vitro. *Lin Chuang Er Bi Yan Hou Ke Za Zhi* 2005; 19(15):680-682.

Gao, J; X-y; Xu F-I; Liu D-y; Lei D-p. Effects of sodium phenylbutyrate alone or in combination with fluorouracil or cisplatin on laryngeal carcinoma Hep-2 cell line. *Zhongguo Xinyao yu Linchuang Zazhi* 2005; 24(10):778-781.

Garcia-Manero, G; Issa, J-P. Histone deacetylase inhibitors: A review of their clinical status as antineoplastic agents. *Cancer Investigation* 2005;23(7):635-642.

Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA: A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies. *Clin Cancer Res.* 7: 2292-2300, 2001.

Goh M., Chen F., Paulsen M.T., Yeager A.M., Dyer E.S., Ljungman M. Phenylbutyrate Attenuates the Expression of Bcl-XL, DNA-PK, Caveolin-1, and VEGF in Prostate Cancer Cells1. *Neoplasia* Vol. 3, No. 4, 2001, pp. 331-338.

Gore SD, Weng LJ, Zhai S, Figg WD, Donehower RC, Dover GJ, Grever M, Griffin CA, Grochow LB, Rowinsky EK, Zabalena Y, Hawkins AL, Burks K, Miller CB: Impact of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia. *Clin Cancer Res.* 7: 2330-9, 2001

Gore SD, Weng LJ, Zhai S, Figg WD, Donehower RC, Dover GJ, Grever M, Griffin CA, Grochow LB, Zabalena Y, Hawkins AL, Burks K and Miller CB. Impact of prolonged infusions of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia. *Clinical Cancer Research* Vol. 8, 963-970, April 2002

Gore, SD; Baylin, S; Sugar, E; Carraway, H; Miller, CB; Carducci, M; Grever, M; Galm, O; Dausess, T; Karp, JE; Rudek, MA; Zhao, M; Smith, BD; Manning, J; Jiemjit, A; Dover, G; Mays, A; Zwiebel, J; Murgo, A; Weng, L-J; Herman, JG. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. *Cancer Res* 2006; 66(12):6361-6369.

Gore, SD; Jiemjit, A; Silverman, LB; Aucott, T; Baylin, S; Carraway, H; Douses, T; Fandy, T; Herman, J; Karp, JE; Licht, JD.; Murgo, AJ.; Odchimar-Reissig, R; Smith, BD; Zwiebel, JA.; Sugar, E. Cimbined methyltransferase/Histone deacetylase inhibition with 5Azacitidine and MS-275 in patients with MDS, CMMoL and AML: Clinical response, Histone Acetylation and DNA damage. *Blood* 2006; 108(11, part 1):156A-157A.

Gore, SD. Do histone deacetylase inhibitors have a place in the treatment of myelodysplastic syndromes? *Leukemia Research* 2007; 31(Suppl. 1):S21.

Gray S.G., Iglesias A.H., Teh B.T., Dangond F., Modulation of Splicing Events in Histone Deacetylase 3 by Various Extracellular and Signal Transduction Pathways Gene Expression, Vol. 11, pp. 13-21. Oct. 2002.

Gray S.G., Quian C.-N., Furge K., Guo X., The B.T., Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. *Int. J of Onc.* 24:773-795, 2004.

Hao, C-I; Tang, K-j; Chen, S, Xing, H-y; Wang, M; Wang, J-x. 5-Aza-2'-deoxycytidine enhances differentiation and apoptosis induced by phenylbutyrate in Kasumi-1 cells. *Zhonghua Zhong Liu Za Zhi* 2005;27(3):148-151.

Hattori, Y; Fukushima, M; Maitani, Y. Non-viral delivery of the connexin 43 gene with histone deacetylase inhibitor to human nasopharyngeal tumor cells enhances gene expression and inhibits in vivo tumor growth. *Int J Oncol* 2007;30(6):1427-1439.

Holm, E; Schade, I. Effects of short-chain and saturated long-chain fatty acids on tumor growth-in vitro and experimental in vivo effects. *Aktuelle Ernährungsmedizin* 2008;33(5):225-230.

Hurtubise, A; Bernstein, ML; Momparler, RL. Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells. *Cancer Cell Int* 2008;8:16.

Huynh, L; Grant, J; Leroux, JC; Delmas, P; Allen, C. Prediction the solubility of the anti-cancer agent docetaxel in small molecule excipients using computational methods. *Pharm Res* 2008; 25:147-157.

Jiemjit, A; Fandy, TE; Baylin, SB; Carraway, H; Herman, JG; Gore, SD. Sequential administration of DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi) induces apoptosis with caspase and reactive oxygen species (ROS)-dependent synergy. *Proceedings of the American Association for Cancer Research Annual Meeting* 2007; 48:249.

Jin C., Park J.W., Choi J.W., Kang H., Jin G.B., Choi S.M., Park S.S., Ryu D., Jang L.C. Antiproliferative Effect of Phenylbutyrate in AsPC-1 Pancreatic Cancer Cell Line. *Korean J. Hepatobiliary Pancreat Surg.* 2006 Mar; 10(1):1-9. Korean

Jin X, Wu N, Dai J, Li Q, Xiao X. TXNIP mediates the differential responses of A549 cells to sodium butyrate and sodium 4-phenylbutyrate treatment. *Cancer Med* Feb 2017;6(2):424-438

Kennedy C., Byth K., Clarke C.L., DeFazio A., Cell Proliferation in the Normal Mouse Mammary Gland and Inhibition by Phenylbutyrate. *Molecular Cancer Therapeutics* Vol. 1, 1025-1033, Oct. 2002.

Kikuchi, M., Yamashita, K., Waraya, N., Ushiku, H., Kojo, K., Ema, A., Kosaka, Y., Katoh, H., Sengoku, N., Enomoto, T., Tanino, H., Sawanobori, M., Watanabe. Epigenetic regulation of ZEB1-RAB25/ESRP1 axis plays a critical role in phenylbutyrate treatment-resistant breast cancer. *Oncotarget*, 7(2): 1741-1753 January 2016

Kim, Y.H., Park, J.W., Lee, J.Y., et al. Sodium Phenylbutyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Ap1 sites in colon Cancer cells. *Carcinogenesis.* 2001;25:1813-20

Kouraklis G., Theocharis S. Histone deacetylase inhibitors: A novel target of anticancer therapy (Review). *Oncology Reports* 15: 489-494, 2006.

Koutsourea, AI; Fousteris, MA; Arsenou, ES; Papageorgiou, A; Pairas, GN; Nikolaropoulos, SS. Rational design, synthesis and in vivo evaluation of the antileukemic activity of six new alkylating steroidal esters. *Bioorg Med Chem* 2008; 16(9):5207-5215.

Kulp, SK; Chen, C-S; Wang, D-S; Chen, C-Y; Chen, C-S. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. *Clin Cancer Res* 2006; 12(17):5199-5206.

L.H. Camacho, J. Olson, W.P. Tong, .W. Young, D.R. Spriggs, M.G. Malkin. Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. *Invest. New Drugs*, 2007 25:131-138.

Lea, MA; Ibeh, C; Shah, N; Moyer, MP. Enhanced differentiation of colon cancer cells induced by combinations of inhibitors of kinases and of histone deacetylases. *Proceedings of the American Association for Cancer Research Annual Meeting 2006*; 47:1184.

Lee Sy, Hong EH, Jeong JY, Cho J, Seo JH, K HJ, Cho HJ. Esterase-sensitive cleavable histone deacetylase inhibitor-coupled hyaluronic acid nanoparticles for boosting anticancer activities against lung adenocarcinoma. *Biomater Sci Nov 2019*;7(11):4624-4635

Linz, Uta, Complete response of a recurrent, multicentric malignant glioma in a patient treated with Phenylbutyrate. *Journal of Neuro-Oncology* 66:251, 2004.

Liu M., Brusilow W.S.A., Needleman R., Activity of the yeast Tat2p tryptophan permease is sensitive to the anti-tumor agent 4-phenylbutyrate. *Curr Genet* 46:256-268 (2004).

Lopez, CA, Feng, FY, Herman, JM, Nyati, MK, Lawrence, TS, Ljungman, M. Phenylbutyrate Sensitizes Human Glioblastoma Cells Lacking Wild-Type P53 Function To Ionizing Radiation. *Int. J. Radiation Oncology Biol. Phys.* Vol. 69, No. 1, PP. 214-220, 2007.

Lu Q, Wang D-S, Chenm C-S, Hu Y-D, Chen C-S. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. *J Med Chem* 2005; 48 (17): 5530-5535.

Lu, Y-S; Kashida, Y; Jung, J-H; Chen, C-S; Wang, Y-C; Cheng, A-L; Chen, C-S. In vivo efficacy of OSH-HDAC42, a novel phenylbutyrate-based histone deacetylase inhibitor, in human hepatocellular carcinoma animal models. *Proceedings of the American Association for Cancer Research Annual Meeting 2007*; 48:169.

Lu, Y-S; Kashida, Y; Kulp, SK; wang, Y-C; Wang, D; Hung, J-H; Tang, M; Lin, Z-Z; Chen, T-J; Cheng, A-L; Chen, C-S. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. *Hepatology* 2007; 46(4):1119-1130.

Lubbert, M; Claus, R. Epigenetic inactivation of gene expression. New therapeutic targets in hematology. *Onkologie* 2007;13(1):46-55. lindsay@customvite.com or service@nutrilab.com.

Luebbert, M. Combined targeting of the epigenetic silence in leukemia: Cooperating activities of DNA methylation and histone deacetylation inhibitors. *Leukemia Research* 2005; 29(7):727-728.

Luebbert, M. Which myelodysplastic syndromes patients are candidates for treatment with decitabine. *Leukemia Research* 2007; 31(Suppl. 1):S20.

Lyon, CM; Klinge, D; Liechty, KC; Belinsky, SA. DNA demethylating agents and a PPA-gamma agonist cooperate to induce apoptosis in lung cancer cell lines. *Proceedings of the American Association for Cancer Research Annual Meeting 2006*; 47:10.

Lyon, CM; Klinge, D; Liechty, KC; Grimes, MJ; Grimes, J; Thomas, C; March, T; Stidley, C; Keith, R; Belinsky, SA. Rosiglitazone prevents the progression of pre-invasive lung cancer in a murine model. *Proceedings of the American Association for Cancer Research Annual Meeting 2007*; 48:395.

Mack, GS. Epigenetic cancer therapy makes headway. *Journal of the National Cancer Institute* 2006;98(20):1443-1444.

Meletis, J; Viniou, N; Terpos, E. Novel agents for the management of myelodysplastic syndromes. *Med Sci Monit* 2006; 12(9):RA 194-RA206.

Meng M., Jiang J.M., Liu H., In C.Y., Zhu J.R. Effects of sodium phenylbutyrate on differentiation and induction of the P21WAF1/CIP1 anti-oncogene in human liver carcinoma cells lines. *Chinese Journal of Digestive Diseases* 2005; 6; 189-192.

Meng, M; Wang, C-T; Jiang, J-M; Zhang, J-C; Jiang, J-J; Jin, C-J. Expression of histone deacetylase 4 in human liver carcinoma cell line Bel-7402 and its significance. *Chinese Journal of Cancer Biotherapy Chin. J. cancer Biother* 2007; 14(2):153-157.

Milkevitch, M; Jeitner, TM; Beardsley, NJ; Delikatny, EJ. Lovastatin enhances phenylbutyrate-induced MR-visible glycerophosphocholine but not apoptosis in DU145 prostate cells. *Biochim Biophys Acta* 2007; 1771(9):1166-1176.

Milkevitch, M; Shim, H; Pilatus, U; Pickup, S; Wehrle, JP; Samid, D; Poptani, H; Glickson, JD; Delikatny, EJ. Increases in NMR-visible lipid and glycerophosphocholine during phenylbutyrate-induced apoptosis in human prostate cancer cells. *Biochim Biophys Acta* 2005; 1734(1):1-12.

Mortazavi, A.; Hoot, DR; Carlton, PS; Wang, S; Degroff, VL.; Lu, Q; Kulp, S; Chen, C-S; Clinton, SK. Inhibition of cell growth and induction of apoptosis in bladder cancer cell lines by a novel histone deacetylase inhibitor derived from phenylbutyrate. *Proceedings of the American Association for Cancer Research Annual meeting 2005*; 46(Supplement S): 422.

Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs MI, Tucker SL, Ismail S, Stevens C, Meyn RE. Histone deacetylase inhibitors radiosensitize human melanoma cell by suppressing DNA repair activity. *Clin Cancer Res* 2005; 11 (13): 4912-4922.

Murahari, S; Jalkanen, AL; Kulp, SK; Chen, C-S; Jubala, CM; Fosmire, SP; Modiano, JF; Fossey, SL; London, CA, Kisseberth, WC. OSU-HDAC42, a novel histone deacetylase inhibitor with potent antitumor effects on human and canine osteosarcoma cells. *Proceedings of the American Association for Cancer Research Annual Meeting 2008*;49:578.

Nakagawa H., Intrathecal or intracavitary administration of sodium butyrate to treat neoplastic meningitis and malignant glioma *Proceedings of the AACR, Vol. 45:5241, March 2004.*

P. Malask, S. Chanel, L.H. Camacho, S. Soignet, P.O. Dandolfi, I. Guernah, R. Warrell, S. Nimer. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. *Leukemia* 2006, 20, 212-217.

Phillips John A., Griffin, Beverly E. Pilot study of sodium Phenylbutyrate as adjuvant in cyclophosphamide-resistant endemic Burkitt's lymphoma. *Royal Society of Tropical Medicine and Hygiene* doi: 10.1016/j.trstmh.2007.06.0200.

Phillips, JA; Griffin, BE. Pilot study of sodium phenylbutyrate as adjuvant in cyclophosphamide-resistant endemic Burkitt's lymphoma. *Trans R Soc Trop Med Hyg* 2007; 101(12):1265-1269.

Phuphanich S, Baker SD, Grossman SA, Carson KA, Gilbert MR, Fisher JD, Carducci MA. Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study. *Neuro-Oncology* Vol 7 pg 177-182, April 2005.

Picard, V; Bergeron, A.; Larue, H; Fradet, Y. MAGE-A9 mRNA and protein expression in bladder cancer. *Int J Cancer* 2007; 120 (10):2170-2177.

Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. *Cancer Research* 61, 1477-85, Feb. 15, 2001.

Qian K, Sun L, Zhou G, Ge H, Meng Y, Li J, Li X, Fang X. Sodium Phenylbutyrate Inhibits Tumor Growth and the Epithelial-Mesenchymal Transition of Oral Squamous Cell Carcinoma In Vitro and In Vivo. *Cancer Biother Radiopharm* May 2018;33(4):139-145

Rudek MA, Zhao M, He P, Hartkle C, Gilbert J, Gore SD., Carducci MA, Baker SD. Pharmacokinetics of 5-Azacytidine Administered With Phenylbutyrate in Patients With Refractory Solid Tumors or Hematologic Malignancies. *Journal of Clinical Oncology* Vol 23 #17 June 10, 2005.

Sachs M.D., Ramamurthy M., van der Poel H., Wickham T.J., Lamfers M., Gerritsen W., Chowdhury W., Li Y., Schoenberg M.P., Rodriguez R. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. *Cancer Gene Therapy* (2004) 11, 477-486.

Sampathkumar S-g, Jones MB, Meledeo MA, Hida K, Sheh T, Gomatputra P, Yarema KJ. Carbohydrate-based small molecules as anti-cancer drugs: Short chain fatty acid-hexosamine hybrids. *Glycobiology* 2005; 15 (11): 1249-1250.

Schniewind B., Heintz K., Kurdow R., Ammerpohl O., Trauzold A., Emme D., Dohrmann P., Kalthoff H. Combination Phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways. *Journal of Carcinogenesis* 2006,1477-3163-5-25.

Shao N, Huang Q, Sun J, Dong J, Wang A, Wang F, Zhu W, A putative pathway in differentiation of SHG-44 glioma cells induced by sodium phenylbutyrate. The Human Genome Organization, HGM2002, Poster 451.

Shi M-G, Huang Q., Dong J, Sun Z-F., Lan Q. Experimental Study of Combination Therapy against Human Glioma Xenograft by Differentiation-Inducing Agent and Cytotoxic Chemotherapeutic Drug. *Chinese Journal of Cancer*, 2002, 21(10): 190-1094.

Shi S, Tan P, Yan B, Gao R, Zhao J, Wang J, Gup J, Li N, Ma Z. ER stress and autophagy are involved in the apoptosis induced by cisplatin in human lung cancer cells. *Oncol Rep* May 2016;35(5):2606-14

Siitonen, T., Koistinen, P., Savolainen, E. Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27Kip1 in acute myeloblastic leukemia cells. *Leukemia Research* 29 (2004) 1335-1342.

Sirchia S.M., Ren M., Pili R.ironi E., Somenzi G., Ghidoni R., Toma S., Nicolo G., Sacchi N.. Endogenous Reactivation of the RAR β 2 Tumor Suppressor Gene Epigenetically Silenced in Breast Cancer *Cancer Research* 62, 2455-2461, May 1, 2002.

Steinmann, J., Halldórsson, S., Agerberth, B., Gudmundsson, G.H. Phenylbutyrate Induces Antimicrobial Peptide Expression. *Antimicrobial Agents and Chemotherapy*, Page. 5127-5133, Vol. 53, December 2009

Sun Li-Jun, Huang Qiang, Lan Qing, Du Zi-wei, Hu Geng-xi, Wang Ai-dong, Gene Expression Profiling of Phenylbutyrate Induced Differentiation of Glioma Cells by cDNA Array. *Chinese Journal of Cancer Research* 15(1):38-42, 2003.

Sun, J; Liu, S; Yu, J; Wei, M; Mao, C; Ding, H; Kearney, J; Huynh, L; Paschka, P; Wang, D; Klisovic, RB; Perrotti, D; Chen, C-S; Blum, WG; Marcucci, G. Characterization of HDACi OSU42 as a novel histone deacetylase inhibitor in AML cell lines. *Blood* 2006; 108(11 Part 1):563A.

Sung, MW; Waxman, S. Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer. *Anticancer Res* 2007;27(2):995-1001.

Svechnikova I, Gray S.G, Kundrotiene J, Ponthan F, Kogner P, Ekström T. Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. *Int. Journal of Oncology* 22: 579-588, 2003.

Svechnikova, I; Ammerpohl, O; Ekstroem, TJ. P21waf1/Cip1 partially mediates apoptosis in hepatocellular carcinoma cells. *Biochem Biophys Res Commun* 2007; 354(2):466-471.

Svechnikova, Irina, Almqvist, Per M., Ekström, Tomas J. HDAC inhibitors effectively induce cell type-specific differentiation in human glioblastoma cell lines of different origin. *International Journal of Oncology* 32:821 - 827, 2008

Tanaka T, Kojima K, Yokota K, Tanaka Y, Ooizumi Y, Ishii S, Nishizawa, Yokoi K, Ushiku H, Kikuchi M, Kojo K, Minatani N, Katoh H, Sato T, Nakamura T, Sawanobori, Watanabe M, Yamashita K. Comprehensive Genetic Search to Clarify the Molecular Mechanism of Drug Resistance Identifies ASCL2-LEF1/TSPAN8 Axis in Colorectal Cancer. *Ann Surg Oncol* May 2019;26(5):1401-1411

Thompson P., Balis F., Baruti M., Berg S.S., Adamson P., Klenk R., Aiken A., Packer R., Murry D.J., Jakacki R., Blaney S.M. Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. *Cancer Chemother Pharmacol* (2003) 52:417-423.

- Verheul, HMW; Qian, DZ; Carducci, MA; Pili, R. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. *Cancer Chemother Pharmacol* 2007; 60(3):329-339.
- Vila-Carriles, WH; Kovacs, GG; Bubien, JK; Gillespie GY; Fuller, CM; Benos, DJ. Cellular localization of acid sensing ion channels in human astrocytes and gliomas. *FASEB Journal* 2006; 20(4, Part1):A325.
- Vila-Carriles, WH; Zhou, Z-H; Bubien, JK; Fuller, CM; Benos, DJ. Participation of the chaperone Hsc70 in the trafficking and functional expression of ASIC2 in glioma cells. *J Biol Chem* 2007;282(47):34381-34391.
- Wanda H. Vila-Carriles, Gergely Gy Kovacs, Biljana Jovov, Zhen-Hong Zhou, Amit K. Pahwa, Garrett Colby, Ogenna Esimai, G. Yancey Gillespie, Timothy B. Mapstone, James M. Markert, Catherine M. Fuller, James K. Bubien, Dale J. Benos. Surface Expression of ASIC2 Inhibits the Amiloride-sensitive Current and Migration of Glioma Cells. *The Journal of Biological Chemistry* VOL. 281, NO> 28, pp. 19220 – 19232, July 14, 2006.
- Wang, C., Meng, M., Zhang, J., Jin, C., Jiang, J., Ren, H., Jiang, J., Qin, C., and Yu, D. *Chinese Medical Journal* 2008; 121(17):1707-1711.
- Wang, H-E; Wu, H-C; Kao, S-J; Tseng, F-W; Wang, Y-S; Yu, H-M; Chou, S-L; Yen, S-H; Chi, K-H. Modulation of 5-fluorouracil cytotoxicity through thymidylate synthase and NF-kappaB down-regulation and its application on the radiolabelled iododeoxyuridine therapy on human hepatoma cell. *Biochem Pharmacol* 2005; 69(4):617-626.
- Welsch, L., Welsch, T., Dovzhanskiy, I., Felix, K., Giese, N.A., Krysko, D. Impact of the histone deacetylase inhibitor 4-phenylbutyrate on the clearance of apoptotic pancreatic carcinoma cells by human macrophages. *International Journal of Oncology*, 2012, 40(2). P. 427-435
- West, DA; Lucas, DM; Davis, ME; De lay, MD; Johnson, AJ; Guster, SE; Freitas, MA; Parthun, MR; Wang, D; Kulp, SK; Grever, MR; Chen, C-S; Byrd, JC. The novel histone deacetylase inhibitor OSU-HDAC42 has class I and II histone deacetylase (HDAC) inhibitory activity and represents a novel therapy for chronic lymphocytic leukemia. *Blood* 2006; 108(11 Part 1): 794A-795A.
- Witt O, Mönkemeyer S, Rönndahl G, Erdlenbruch B, Reinhardt D, Kanbach K, and Pekrun A. Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. *Blood*, Mar 2003; 101: 2001 - 2007.
- X.-N. Li, S. Parikh, Q. Shu, H.-L. Jung, C.-W. Chow, L. Perlaky, H.-C. E. Leung, J. Su, S. Blaney, and C. C. Lau Phenylbutyrate and Phenylacetate Induce Differentiation and Inhibit Proliferation of Human Medulloblastoma Cells *Clin. Cancer Res.*, February 1, 2004; 10(3): 1150 - 1159.
- Xu YW, Xheng SB, Chen BS, Wen Y, Zhu SW. Effect of sodium phenylbutyrate on the sensitivity of PC3/DTX-resistant prostate cancer cells to docetaxel. *Nan Fang Yi Ke Da Xue Xue Bao* Nov 2017;37(1):130- 134
- Xu, X., Zheng, S., Chen, B., Wen, Y., Zhu, S. sodium Phenylbutyrate antagonizes prostate cancer through the induction of apoptosis and attenuation of cell viability and migration. *Onco Targets & Therapy*, May 12, 2016, 9: 2825-2833
- Zhang X., Wei L., Yang Y., Yu Q. Sodium 4-Phenylbutyrate Induces Apoptosis of Human Lung Carcinoma Cells Through Activating JNK Pathway. *Journal of Cellular Biochemistry* 93:819-829 (2004).
- Zhu Q, Zhang J-W, Zhu H-Q, Shen Y-L, Flexor M, Jia P-M, Yu Y, Cai X, Waxman S, Lanotte M, Chen S-J, Chen Z, and Tong J-H. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. *Blood*, Feb 2002; 99: 1014 - 1022.

CARDIAC INJURY

Daosukho,C., Chen, Y., Noel, T., Sompol, P., Nithipongvanitch, R., Velez, J.M., Oberley, T.D., St. Clair, D.K. Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury. *Free Rauduc Bio Med.* 42(12):1818-1825 June 15, 2007.

Jain K, Suryakumar G, Ganju L, Singh SB. Amelioration of ER stress by 4-phenylbutyric acid reduces chronic hypoxia induced cardiac damage and improves hypoxic tolerance through upregulation of HIF-1a. *Vascul Pharmacol* Aug 2016;83:36-46

Jian L, Lu Y, Lu S, Lu C. Chemical Chaperone 4-Phenylbutyric Acid Reduces Cardiac Ischemia/Reperfusion Injury by Alleviating Endoplasmic Reticulum Stress and Oxidative Stress. *Med Sci Monit* Dec 2016;22:5218-5227

Okajima, M., Takamura, M., Usui, S., Kaneko, S. Sodium 4-phenylbutyrate protects against myocardial ischemia-reperfusion injury by reducing unfolded protein response-mediated apoptosis in mice. 30th International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium March 9-12, 2010

Takatori O, Usui S, Okajima M, Kaneko S, Ootsuji H, Takashima SI, Kobayashi D, Murai H, Furusho H, Takamura M. Sodium 4-Phenylbutyrate Attenuates Myocardial Reperfusion Injury by Reducing the Unfolded Protein Response. *J Cardiovasc Pharmacol Ther* May 2017;22(3):282-292

Zhang Z, Zhao L, Zhou Y, Lu X, Wang Z, Wang J, Li W. Taurine ameliorated homocysteine-induced H9C2 cardiomyocyte apoptosis by modulating endoplasmic reticulum stress. *Apoptosis* May 2017;22(5):647-661.

CEREBRAL ISCHEMIC INJURY

Krishnamoorthy S, Sharma SS. Sodium phenylbutyrate ameliorates focal cerebral ischemic/reperfusion injury associated with comorbid type 2 diabetes by reducing endoplasmic reticulum stress and DNA fragmentation. *Behav Brain Res* Nov 2011;225(1):110-6

Lei J., Wang, B., Feng, D., Huang, L., Li, Y., Li, T., Zhu, G., Li, C., Li, F., Gao, G., Li, G. Pretreatment with Sodium Phenylbutyrate Alleviates Cerebral Ischemia/Reperfusion Injury by Upregulating DJ-1 Protein. *Frontiers Neurol.*, June 9, 2017.

Qi X., Hosoi T., Okuma Y., Kaneko M., Nomura Y., Sodium 4-Phenylbutyrate Protects against Cerebral Ischemic Injury, *Molecular Pharmacology* 66:899-908, 2004.

CYSTIC FIBROSIS

Céline René, Magali Taulan, Florence Iral, Julien Doudement, Aurore L'Honoré, Catherine Gerbon, Jacques Demaille, Mireille Claustres and Marie-Catherine Romey, Binding of serum response factor to cystic fibrosis transmembrane conductance regulator CArG-like elements, as a new potential CFTR transcriptional regulation pathway. *Nucleic Acids Research*, Vol. 33, No. 16, 5271-5290, 2005.

Claudiu Iordache, Marek Duszyk. Sodium 4-Phenylbutyrate upregulates EnaC and sodium absorption in T84 cells. *Experimental Cell Research* 313 (2007) 305-311

Farinha Carols M., Nogueira, Paulo, Mendes, Filipa, Penque, Deborah and Amaral, Margarida D. The human Dnaj homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70. *Biochem. J.* (2002) 366, 797-806.

Kerem E. Pharmacological Induction of CFTR Function in Patients with Cystic Fibrosis: Mutation-Specific Therapy. *Pediatric Pulmonology* 40:183-196 (2005).

Lim M., McKenzie K., Floyd A.D., Kwon E., Zeitlin P.L. Modulation of $\Delta F508$ Cystic Fibrosis Transmembrane Regulator Trafficking and Function with 4-Phenylbutyrate and Flavonoids. *Am. J. Respir. Cell Mol. Biol.* Vol. 31, pp. 351-357, 2004.

Poschet J.F., Skidmore J., Bouchjer J.C., Firoved A.M., Van Dyke R.W., Deretic V. Hyperacidification of Cellubrevin Endocytic Compartments and Defective Endosomal Recycling in Cystic Fibrosis Respiratory Epithelial Cells, *The Journal of Biological Chemistry* Vol. 277, No. 16, April 2002

Prulière-Escabasse, V., Planès, C., Escudier, E., Fanen, P., Coste, A., Clerici, C. Modulation of Epithelial Sodium Channel Trafficking and Function by Sodium 4-Phenylbutyrate in Human Nasal Epithelial Cells. *Journal of Biological Chemistry* September 2007

Roomans G.M. Pharmacological Approaches to Correcting the Ion Transport Defect in Cystic Fibrosis. *Am J. Respir Med.* 2003; 2(5):413-431

Roque, T., Boncoeur, E., Saint-Criq, V., Bonvin, E., Clement, A., Tabary, O., Jacquot, J. Pro-inflammatory effect of sodium 4-phenylbutyrate in $\Delta F508$ -CFTR lung epithelial cells: Involvement of ERK1/2 and JNK signaling. *JPET*, June 23, 2008, DOI:10.1124/jpet.107.135186

Singh O.V., Vij N., Mogayzel Jr. P.J., Jozwik C., Pollard H.B., Zeitlin P. L., Pharmacoproteomics of 4-Phenylbutyrate-treated IB3-1 Cystic Fibrosis Bronchial Epithelial Cells. *Journal of Proteome Research* 2006, 5, 562-571.

Singh OV, Pollard HB, Zeitlin, PL. Chemical Rescue of $\Delta F508$ -CFTR Mimics Genetic Repair in Cystic Fibrosis Bronchial Epithelial Cells. *Molecular & Cellular Proteomics* 7.5, February, 2008.

Suaud L, Mikker K, Panichelli AE, et al. 4-Phenylbutyrate stimulates Hsp 70 expression through the Elp2 component of elongator and STAT-3 in cystic fibrosis epithelial cells. *Journal Biol Chem* 2011, Dec 30; 286(52):45083-92

Suaud L, Rubenstein RC. Activation of STAT-3 in CF epithelial cell by Sodium 4-Phenylbutyrate. *FASEB Journal* 2005; 19 (4, Suppl. S, Part 1): A658.

Vij, Neeraj, Fang, Shengyun and Zeitlin, Pamela L. Selective Inhibition of Endoplasmic Reticulum-associated Deradation Rescues $\Delta F508$ -Cystic Fibrosis Transmembrane Regulator and Suppresses Interleukin-8 Levels. *The Journal of Biological Chemistry*, Vol. 281, No. 25 pp. 17369-17378, June 23, 2006.

Virginie Prulière-Escabasse, Carole Planès, Estelle Escudier, Pascale Fanen, André Coste, Christine Clerici. Modulation of Epithelial Sodium Channel Trafficking and Function by Sodium 4-Phenylbutyrate in Human Nasal Epithelial Cells. *JBC Papers in Press*, September 21, 2007, DOI 10.1074/jbc.M702384200.

Wang W-J., Mulugeta S., Russo S.J., Beers M.F., Deletion of exon 4 from human surfactant protein C results in aggresome formation and generation of a dominant negative, *Journal of Cell Science* 116, 683-692, 2003.

Wright J.M., Zeitlin P.L., Cebotaru L., Guggino S.E., Guggino W.B., Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins. *Physiol Genomics* 16:204-211, 2004.

Zeitlin, P., Diener-West, M., Rubenstein, R., Boyle, M., Lee, C., Brass-Ernst, L. Evidence of CFTR Function in Cystic Fibrosis after Systemic Administration of 4-Phenylbutyrate. *Molecular Therapy*, Vol. 6, No. 1, July 2002.

EPILEPSY

Berthier A, Payá M, Garcia-Cabrero AM, Ballester MI, Heredia M, Serratosa JM, Sánchez MP, Sanz P. Pharmacological Interventions to Ameliorate Neuropathological Symptoms in a Mouse Model of Lafora Disease. *Mol Neurobiol* Mar 2016;53(2):1296-1309

Bogdanovic, M.D., Kidd, D., Briddon, A., Duncan, J.S., Land, M.M. Late onset heterozygous ornithine transcarbamylase deficiency mimicking complex partial status epilepticus. *J. Neurol. Neurosurg Psychiatry*, 2000, 69:813-815

Loron AG, Sardari S, Narenjkar J, Sayyah M. In silico Screening and Evaluation of the Anticonvulsant Activity of Docosaheptaenoic Acid-Like Molecules in Experimental Models of Seizures. *Iran Biomed J* Jan 2017;21(1):32-9

Sánchez-Elexpuru G, Serratosa JM, Sanz P, Sánchez MP. 4-Phenylbutyric acid and metformin decrease sensitivity to pentylenetetrazol-induced seizures in a malin knockout model of Lafora disease. *Neuroreport* Mar 2017;28(5):268-271

Weise S, Syrbe S, Preuss M, Bertsche A, Merckenschlager A, Bernhard MK. Pronounced reversible hyperammonemic encephalopathy associated with combined valproate-topiramate therapy in a 7-year old girl. *Springerplus* June 2015;4:276

Yokoi N, Fukata Y, Kase D, Miyazaki T, Jaegle M, Ohkawa T, Takahashi N, Iwanari H, Mochinzuki Y, Hamakubo T, Imoto K, Meijer D, Watanabe M, Fukata M. Chemical corrector treatment ameliorates increased seizure susceptibility in a mouse model of familial epilepsy. *Nat Med* Jan 2015;21(1):19-16.

EYE

Christopher Kai-shun Leung, Chinese University of Hong Kong, Sodium 4-Phenylbutyrate has the ability to prevent steroid-induced glaucoma. Press Release August 17, 2010

Gary Hin-Fai Yam, Katarina Gaplovska-Kysela, Christian Zuber, Jürgen Roth. Sodium 4-Phenylbutyrate Acts as a Chemical Chaperone on Misfolded Myocilin to Rescue Cells from Endoplasmic Reticulum Stress and Apoptosis. *Investigative Ophthalmology & Visual Science*, April 2007, Vol. 48, No.4.

Gong Bo, Zhang Li-Yun, Lam Dennis Shun-Chiu, Pang Chi-Pui, Yam Gary Hin-Fai. Sodium 4-phenylbutyrate ameliorates the effects of cataract-causing mutant gammaD-crystallin in cultured cells. *Molecular Vision* 2010 June 4, 2010

Jeng Y-Y, Lin N-T, Chang P-H, Huang Y-P, Pang VF, Liu C-H, Lin C-T. Retinal ischemic injury rescued by sodium 4-phenylbutyrate in a rat model. *Exp Eye Res* 2007; 84 (3): 486-492.

Roth J, Yam GH-F, Gaplovska-Kysela K, Zuber C. Russell body formation and apoptosis in myocilin-caused primary open-angle glaucoma; rescue by the chemical chaperone sodium 4-phenylbutyrate. *FASEB Journal* 2007; 21 (5): A182.

Yung-Yue Jeng, Nien-Ting Lin, Pen-Heng Chang, Yuan-Ping Huang, Victor Fei Pang, Chen-Hsuan Liu, Chung-Tien Lin. Retinal ischemic injury rescued by sodium 4-phenylbutyrate in a rat model. *Experimental Eye Research* (84 (2007) 486-492.

Zode GS, Bugge KE, Mohan K, et al. Topical ocular sodium 4-phenylbutyrate rescues glaucoma in a myocilin mouse model of primary open-angle glaucoma. *Invest Ophthalmol Vis Sci* 2012 Mar; 53(3):1557-65.

HUNTINGTON'S DISEASE

Borovecki F., Lovrecic L. Zhou J., Jeong H., Then F., Rosas H.D., Hersch S.M., Hogarth P., Bouzou B., Jensen R.V., Krainc D. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. *PNAS* August 2, 2005, Vol. 102 No. 31 (11023-11028).

Ebbel, E.N., Leymarie, N., Schiavo, S., et al. Identification of Phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography/electrochemical array/mass spectrometry and off-line tandem mass spectrometry. *AnalyticalBiochem.* 2010; 399(2):153-61

Ferrante R.J., Kubilus J.K., Lee J., Ryu H, Beesen A., Zucker B., Smith K., Kowall N. W., Ratan R. R., Luthi-Carter R., Hersch S.M., Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice. *J Neurosci* 2003; 23 (28): 9418-9427.

Gardian G., Browne S.E., Choi D-K., Klivenyi P., Gregorio J., Kubilus J.K., Ryus H., Langley B., Ratan R.R., Ferrante R.J., Beal M.F. Neuroprotective Effects of Phenylbutyrate in the N171-82Q Transgenic Mouse Model of Huntington's Disease. *The Journal of Biological Chemistry* Vol. 280, No.1, Jan. 7, 2005 (556-563).

Hogarth, P, Lovrecic, L, Kraine, D. Sodium Phenylbutyrate in Huntington 's disease: A Dose-Finding Study. *Movement Disorders*, 2007, Vol. 22, No. 13.

Naia L, Cunha-Oliveria T, Rodrigues J, Rosenstock TR, Oliveria A, Ribeiro M, Carmo C, Oliveria-Sousa S, Duarte A, Hayden MR, Rego AC. *J Neurosci* Mar 2017;37(10):2776-2794

Sadri-Vakili, Ghazaleh and Cha, Jang-Ho J. Mechanisms of Disease: histone modifications in Huntington's disease. *Nature Clinical Practice Neurology*, June 2006, Vol. 2, No. 61.

Tolchin, E. Biomarkers of Huntington's Disease Found in Blood 7/26/05. *Bioscience Technology*, <http://www.biomedicalproducts.com>

Upagupta C, Carlisle RE, Dickhout JG. Analysis of the potency of various low molecular weight chemical chaperones to prevent protein aggregation. *Biochem Biophys Res Commun* Apr 2017; 486(1):163-170.

KIDNEY/RENAL

Bhardwaj R, Tandon C, Dhawan DK, Kaur T. Effect of endoplasmic reticulum stress inhibition of Hyperoxaluria-induced oxidative stress; influence on cellular ROS sources. *World J Urol* Dec 2017;35(12):1955-1965

Bonnemaison ML, Marks-Nelson ES, Boesen EI. Sodium 4-phenylbutyrate treatment protects against renal injury in NZBWF1 mice. *Clin Sci (Lond)* Jan 2019;133(2):167-180

Carlisle RE, Brimble E, Werner KE, Cruz GL, Ask K, Ingram AJ, Dickhout JG. 4-Phenylbutyrate inhibits tunicamycin-induced acute kidney injury via CHOP/GADD153 repression. *PLoS One* Jan 2014;9(1):e84663

Choi S.W., Ryu O.H., Choi S.J., Song I.S., Bleyer A.J., Hart T.C. Mutant Tamm-Horsfall Glycoprotein Accumulation in Endoplasmic Reticulum Induces Apoptosis Reversed by Colchicine and Sodium 4-Phenylbutyrate. *J. Am. Soc. Nephrol.* 16:3006-3014, 2005.

Guo J, Zhu J, Ma L, Shi H, Hu J, Zhang S, Hou L, Xu F, An Y, Yu H, Ge J. Chronic Kidney Disease Exacerbates Myocardial Ischemia Reperfusion Injury; Rol of Endoplasmic Reticulum Stress-Mediated Apoptosis. *Shock* Jun 2018;49(6):712-720

Karoui Ke, Viau A, Dellis O, Bagattin A, Nguyen C, Baron W, Burtin M, Broueilh M, Heidet L, Mollet G, Druilhe A, Antignac C, Knebelmann B, Friedlander G, Bienaime F, Gallazzini M, Terzi F. Endoplasmic reticulum stress drives proteinuria-induced kidney lesions via Lipocalin 2. *Nat Commun* Jan 2016; 7:10330

Kemter E, Sklenak S, Rathkolb B, de Angelis MH, Wolf E, Aigner B, Wanke R. No amelioration of uromodulin maturation and trafficking defect by sodium 4-phenylbutyrate in vivo: studies in mouse models of uromodulin-associated kidney disease. *J Biol Chem* Apr 2014;289(15):10715-26

Kolb PS, Ayaub EA, Zhou W, Yum V, Dickout JG, Ask K. The therapeutic effects of 4-phenylbutyric acid in maintaining proteostasis *Int J Biochem Cell Biol* Apr 2015;1:45-52

Liu SH, Yang CC, Chan DC, Wu CY, Chen LP, Huang JW, Hung KY, Chiang CK. Chemical chaperon 4-phenylbutyrate protects against the endoplasmic reticulum stress-mediated renal fibrosis in vivo and in vitro. *Oncotargets* Apr 19, 2016, 7(16): 22116-22127

Liu X.L., Cotta Done S., Yan K., Kilpelainen P., Pikkarainen T., Tryggvason K. Defective Trafficking of Nephtrin Missense Mutants Rescued by a Chemical Chaperone. *J. Am. Soc. Nephrol.* 15:1731-1739, 2004.

Liu Xiao Li, Nephtrin cellular trafficking and intracellular interactions, Division of Matrix Biology Dept. of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, May 2004.

Mohammed-Ali Z, Lu C, Marway MK, Carlisle RE, Ask K, Lukic D, Krepinsky JC, Dickhout JG. Endoplasmic reticulum stress inhibition attenuates hypertensive chronic kidney disease through reduction in proteinuria. *Sci Rep* Feb 2017; 7:41572

Randhawa R, Bhardwaj R, Kaur T. Amelioration of hyperoxaluria-induced kidney dysfunction by chemical chaperon 4-phenylbutyric acid. *Urolithiasis* Apr 2019;47(2):171-179

Uggenti C, Briant K, Streit AK, Thomson S, Koay YH, Baines RA, Swanton E, Manson FD. *Dis Model Mech* Nov 2016;9(11):1317-1328

MULTIPLE SCLEROSIS (MS)



Dasgupta S, Zhou Y, Jana M, Banik NL, Pahan K. Sodium Phenylacetate Inhibits Adoptive Transfer of Experimental Allergic Encephalomyelitis in SJL/J Mice at Multiple Steps. *J Immunology* 2003, 170:3874-3882.

MUSCULAR DYSTROPHY

Begam, Morium, Abro, Valerie M, Mueller, Amber L., Roche, Joseph A. Sodium 4-Phenylbutyrate reduces myofiber damage in a mouse model of Duchenne muscular dystrophy. *Appl Physiol Nutr Metab*, October 2016, 41(10):1108-1111.

PARKINSON'S DISEASE

Chompoopong S, Jarungjitaree S, Punbanlaem T, Rungruang T, Chongthammakun S, Kettawan, A, Taechowisan T. Neuroprotective Effects of Germinated Brown Rice in Rotenone-Induced Parkinson's-Like Disease Rats. *Neuromolecular Med* Sept 2016; 18(3):334-46

Gardian, G., Yang, L., Cleren, C., Calingasan, N.Y., Klivenyi, P., and Beal, N.F. Neuroprotective Effects of Phenylbutyrate Against MPTP Neurotoxicity. *NeuroMolecule Medicine*, 2005 Volume 5

Inden M, Kitamura Y, Takeuchi H, Yanagida T, Takata K, Kobayashi Y, Taniguchi T, Yoshimoto K, Kaneko M, Okuma Y, Taira T, Ariga H, Shimohama S. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. *J Neurochem* 2007; 101(6):1491-1504.

Kubota, Kyoko, Niinuma, Yoshifumi, Kaneko, Masayuki, Okuma, Yasunobu, Sugai, Mami, Omura, Tomohiro, Uesugi, Mai, Uehara, Takashi, Hosoi, Toru, Nomura, Yasuyuki. Suppressive effects of 4-Phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. *Journal of Neurochemistry*, 2006, 97, 1259-1268

Roy, A., Ghosh A., Jana A., Liu X., Brahmachari S., Gendelman HE., Pahan K. Sodium Phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease. *PLoS*, 2012;7(6):e38113.doi:10.1371/journal.pone.0038113.

Tamaki A, Yanagida T, Kitamura Y, Takata K, Taniguchi T. Neuroprotective effect of chemical chaperone 4-Phenylbutyrate on rotenone-induced dopaminergic neurodegeneration. *Journal of Pharmacological Sciences* 2008;106 (suppl. 1);233P.

Zhou, W., Bercury, K., Cumiskey, J., Luong, N., Lebin, J., Freed, C.R. Phenylbutyrate Upregulates DJ-1

and Protects Neurons in Cell Culture and in Animal Models of Parkinson's Disease. JBC Papers. March 3, 2011.

SICKLE CELL ANEMIA, THALASSEMIA & COOLEY'S ANEMIA

Hines P, Dover GJ, Resar LMS. Pulsed-dosing with oral sodium Phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia. *Pediatr Blood Cancer* 2008; 50 (2): 357-359.

Odièvre M, Brun M, Krishnamoorthy R, lapoumérولية and Elion J. Sodium Phenylbutyrate Down regulates Endothelin-1 Expression in Cultured Human Endothelial Cells: Relevance to Sickle-Cell Disease. *American Journal of Hematology*, 82:357-362, 2007.

Pace BS, White GL, Dover GJ, Boosalis MS, Faller DV, and Perrine SP. Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. *Blood*, 15 December 2002, Vol. 100, No. 13, pp. 4640-4648

Perrine S, Trudel M, Castaneda SA, Mankidy R, Boosalis MS, Mpollo M-SEM, White GL, Bohacek R, Faller DV. A new generation of gamma globin gene inducers act on novel molecular and cellular targets. *Blood* 2006; 108 (11, Part 1): 453A.

Perrine SP. Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. *Pediatr Ann* 2008; 37 (5): 339-346.

Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP. Fetal haemoglobin augmentation in E/β0 thalassaemia: clinical and haematological outcome. *British Journal of Haematology*, 2005, 131, 378-388

Thompson AA. Advances in the management of sickle cell disease. *Pediatr Blood Cancer* 2006; 45 (5): 533-539.

Witt, Olaf, Mönkemeyer, Sven, Rönndahl, Gabi, Erdlenbruch, Bernhard, Reinhardt, Dirk, Kanbach, Katrin and Pekrun, Arnulf. Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. *Blood*, March 1, 2003, Volume 101, Number 5

Xing H, Zhang S, Koeffler HP, Fung, MC. Cucurbitacin D Upregulates fetal hemoglobin expression in K562 cells and human erythroid progenitors. *Blood* 2007; 110 (11, Part 2): 26B-27B.

SPINAL MUSCULAR ATROPHY

Andreassi C., Angelozzi C., Tiziano F.D., Vitali T., De Vincenzi E., Boninsegna A., Villanova M., Bertini E., Pini A., Neri G., Brahe C. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. *European Journal of Human Genetics* (2004) 12, 59-65

Bosboom, WM, Vrancken, AF, van den Berg, LH, Wokke, JH, Iannaccone, ST. Drug treatment for spinal muscular atrophy types II and III. *Cochrane Database Syst Rev* 2009 ; 1 : CD006282.

Brahe C., Vitali T., Tiziano F.D., Amgelozzi C., Pinto A.M., Borgo F., Moscato U., Bertini E., Mercuri E., Neri G. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. *European J. of Human Genetics* (2005) 13, 256-259.

Darras, BT, Kang, PB. Clinical trials in spinal muscular atrophy. *Curr Opin Pediatr* 2007; 19 (6): 675-679.

Davies S.L., Moral M.A. Spinal muscular atrophies – distinctions and therapeutic progress. *Drugs of the*

Dayangaç-Erden, Topaloğlu, Haluk, Erdem-Yurter, Hayat, A Preliminary Report on Spinal Muscular Atrophy Lymphoblastoid Cell Lines : Are They an Appropriate Tool for Drug Screening ? *Adv Ther* 2008 ;25(3) :274-279.

Dayangaoc-Erden, D, TopaloAlu, H, Erdem-Yurter, H. A preliminary report on spinal muscular atrophy lymphoblastoid cells lines : are they an appropriate tool for drug screening *Adv Ther* 2008; 25 (3) : 274-279.

Ganta M, Grzeschik SM, Heavlin WD, Wang CH. Phenylbutyrate modulates multiple neuronal survival gene expression in SMA cells. *Annals of Neurology* 2006; 60 (Suppl. 10): S140.

Hauke, J, Riessland, M, Lunke, S, Eyoupoglu, IY, Bloumche, I, El-Osta, A, Wirth, B, Hahnen E. Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. *Hum Mol Genet* 2009 ; 18 (2) : 304-317.

Lunn, M.R., Wang, C.H. Spinal Muscular Atrophy. *Lancet* 2008 ; 371 (9630) :2120-33

Mercuri E., Bertini E., Messina S., Pelliccioni M., D'Amico A., Colitto F., Mirabella M., Tiziano F.D., Vitali T., Angelozzi C., Kinali M., Main M., Brahe C. Pilot trial of phenylbutyrate in spinal muscular atrophy. *Neuromuscular Disorders* Vol 14, Issue 2,(130-135) Feb 2004.

Mercuri, E., Bertini E., Messina S., Solari, A. etal. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. *Neurology* 2007;68:1-1

Schwartz, M. The molecular-genetic background of spinal muscular atrophy: Diagnosis, prognosis and future treatments. *Ugeskr Laeg* 2005: 167 (7): 745-748.

Swoboda, KJ. Prospective evaluation of pre-symptomatic infants with spinal muscular atrophy: Implications for early therapeutic intervention. *Annals of Neurology* 2007; 62 (Suppl. 11): S2.

Wirth, B, Brichta, L, Hahnen, E. Spinal muscular atrophy and therapeutic prospects. *Prog Mol Subcell Biol* 2006; 44: 109-132.

Wirth, B, Brichta, L, Hahnen, E. Spinal muscular atrophy: from gene to therapy. *Semin Pediatr Neurol* 2006; 13 (2): 121-131.

Wirth, B, Brichta, L, Schrank, B, Lochmouller, H, Blick, S, Baasner, A, Heller, R. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. *Hum Genet* 2006; 119 (4): 422-428

UREA CYCLE DISORDER/ ORNITHINE TRANSCARBAMYLASE DEFICIENCY

Bachmann C. Long-term outcome of urea cycle disorders. *Acta Gastroenterol Belg* 2005; 68 (4): 466-468.

Batchaw ML., MacArthur RB, Tuchman M., Alternative pathway therapy for urea cycle disorders: twenty years later. *J Pediatr.*, 138 (1 Suppl):S46-54; discussion S-54-5. Jan 2001.

Bhattacharya K, Briddon A, Lee PJ. A review of biochemical outcomes of adults with OTC deficiency. *Journal of Inherited Metabolic Disease* 2007; 30 (Suppl. 1): 82.

Burlina A.B., Ogier H., Korall H., Trefz F.K. Long-term treatment with Sodium Phenylbutyrate in ornithine transcarbamylase-deficient patients. *Molecular Genetics and Metabolism* 72, 3512-355 March 2001

C Vilatoba M, Eckstein C, Bilbao G, Smyth CA, Jenkins S, Thompson JS, Eckhoff De, Contreras JL. Sodium 4-phenylbutyrate protects against liver ischemia reperfusion injury by inhibition of endoplasmic reticulum stress mediated apoptosis. *Surgery* 2005; 138 (2): 342-351.

Dobbelaere DD. Sodium phenylbutyrate (Ammonaps) in the treatment of patients with urea cycle disorders – European post-approval data. *Journal of Inherited Metabolic Disease* 2008; 31 (Suppl. 1): 92.

Eather G, Coman D, Lander C, J. McGill Carbamyl phosphate synthase deficiency: Diagnosed during

pregnancy in a 41-year-old. *Case Reports/Journal of Clinical Neuroscience* 13 2006: 702-706.

Horslen S.P., McCowan T.C., Goertzen T.C., Warkentin P.I., Cai H.B., Strom S.C., Fox I.J. Isolated Hepatocyte Transplantation in an Infant with Severe Urea Cycle Disorder. *Pediatrics* Vol. 111 No. 6 June 2003.

Kern RM, Yang Z, Kim PS, Grody WW, Iyer RK, Cederbaum SD. Arginase induction by sodium phenylbutyrate in mouse tissues and human cell lines. *Molecular Genetics and Metabolism* 90 (2007) 37.41.

Lee B, Garovoy MR, Gargosky SE, Berry SA. Preliminary data on adult patients with urea cycle disorder (UCD) in an open-label, switch-over, does-escalation study comparing a new ammonia scavenger glyceryl tri (4-phenylbutyrate) (HPN-100), to buphenyl (sodium phenylbutyrate – PBA). *Journal of Inherited Metabolic Disease* 2008; 31 (Suppl. 1): 91.

Lee B, Rhead W, Diaz GA, et al. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. *Mol Genet Metab* 2010 Jul; 100(3):221-08

Legras A., Labarthe F., Maillot F., Garrigue M-A., Kouatchet A., Ogier de Baulny H., Late diagnosis of ornithine transcarbamylase defect in three related female patients: Polymorphic presentations. *Crit. Care Med.* 2002 Vol. 30, No. 1.

Leonard JV, Ward P, Martin P, Morris AAM. Hypothesis: proposals for the management of a neonate at risk of hyperammonaemia due to a urea cycle disorder. *Eur J Pediatr* 2008; 167 (3): 305-309.

Maillot F, Crenn P. Urea cycle disorders in adult patients. *Revue Neurologique (Paris)* 2007; 163 (10): 897-903.

Peña-Quintana, L., Llarena, M., Reyes-Suárez D., Aldámiz-Echevarria, L. Profile of sodium phenylbutyrate granules for the treatment of urea-cycle disorders: patient perspectives. *Patient Preference and Adherence* September 6, 2017, 11: 1489-1496

Saha AS, Langridge P, Playfor SD. The pattern of intravenous drug administration during the transfer of critically ill children by a specialist transport team. *Paediatr Anaesth* 2006; 16 (10):1063-1067

Singh RH, Acosta PB, Kennedy MP, Longo N, Elsas LJ. Potassium retention in patients treated for argininosuccinate lyase deficiency. *Journal of Inherited Metabolic Disease* 2006; 29 (1): 48.

Summar M., Current strategies for the management of neonatal urea cycle disorders. *J. of Pediatrics*, (138: S30-S39) Jan. 2001.

Tuchman M, Lee B, Lichter-Konecki U, Summar ML, Yudkoff M, Cederbaum SD, Kerr DS, Diaz GA, Seashore MR, Lee HS, McCarter RJ, Batshaw ML. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Urea Cycle Disorders Consortium of the Rare Diseases Clinical Work Network, *Mol Genet Metab* 2008; 94 (4): 397-402.

Wright GA, Davies NA, Ytrebo LM, Stadlbaure V, Fuskevag O-m, Zwigmann C, Hodges S, Jalan R. L-ornithine Phenylacetate reduces arterial ammonia, improves brain osmolytes and reduces brainwater in a bile duct ligated rat model of cirrhosis. *Hepatology* 2007; 46 (4, Suppl S): 604A-605A.

Wuebbels BH. Outcomes among male OTC patients treated with Ammonaps. *Journal of Inherited Metabolic Disease* 2006; 29 (Suppl 1): 129.

DISCLAIMER: The information presented is intended for educational purposes only for investigators and sponsors of clinical trials that are the subject of an investigational new drug application.



Scandinavian Formulas

140 East Church Street, Sellersville PA 18960 USA

Tel: 215-453-2507 Fax: 215-257-9781 info@spb11.com

